In a phase 1/2 study (RELATIVITY‐020 part D) of rela/niv in advanced melanoma, two cohorts were established: part D1 allowed only one line of a prior anti‐PD‐1‐containing regimen and part D2 allowed multiple prior lines of anti‐PD‐1/L1‐containing regimens.50 The gene discussed is PDCD1; the disease is melanoma.